GLUE - Monte Rosa Therapeutics - Stock Forecast

Coverage Performance Price Targets & Ratings Chart Insider Trading

GLUE is currently covered by 4 analysts with an average price target of $12.01. This is a potential upside of $5.95 (98.18%) from yesterday's end of day stock price of $6.06.

Monte Rosa Therapeutics's activity chart (see below) currently has 4 price targets and 13 ratings on display. The stock rating distribution of GLUE is 55.56% HOLD and 44.44% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 33.33% with an average time for these price targets to be met of 22.4 days.

Highest price target for GLUE is $11, Lowest price target is $10, average price target is $12.01.

Most recent stock forecast was given by ERIC JOSEPH from JPMORGAN on 09-Nov-2023. First documented stock forecast 19-Jul-2021.

Best performing analysts who are covering GLUE - Monte Rosa Therapeutics:

Andrew Berens Derek Archila Edward Tenthoff Richard Law Eric Joseph

Currently out of the existing stock ratings of GLUE, 5 are a HOLD (55.56%), 4 are a BUY (44.44%).

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

10

$2.49 (33.16%)

11

5 months 10 days ago

1/3 (33.33%)

$6.7 (203.03%)

38

Hold

11

$3.49 (46.47%)

11

8 months 8 days ago

0/4 (0%)

$4.31 (64.42%)

Hold

18

$10.49 (139.68%)

19

1 years 3 months 20 days ago

0/2 (0%)

$10.39 (136.53%)

Buy

21

$13.49 (179.63%)

40

1 years 11 months 7 days ago

1/3 (33.33%)

$13.27 (171.67%)

45

Hold

20

$10.81 (117.63%)

2 years 5 months 29 days ago

1/1 (100%)

$-4.92 (-19.74%)

29

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is GLUE (Monte Rosa Therapeutics) average time for price targets to be met?

On average it took 22.4 days on average for the stock forecasts to be realized with a an average price target met ratio 33.33

Which analyst has the current highest performing score on GLUE (Monte Rosa Therapeutics) with a proven track record?

ANDREW BERENS

Which analyst has the current lower performing score on GLUE (Monte Rosa Therapeutics) with a proven track record?

ERIC JOSEPH

Which analyst has the most public recommendations on GLUE (Monte Rosa Therapeutics)?

Andrew Berens works at LEERINK and has 17 price targets and 9 ratings on GLUE

Which analyst is the currently most bullish on GLUE (Monte Rosa Therapeutics)?

Edward Tenthoff with highest potential upside - $13.49

Which analyst is the currently most reserved on GLUE (Monte Rosa Therapeutics)?

Eric Joseph with lowest potential downside - $2.49

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?